LEO LUZNIK to Histocompatibility
This is a "connection" page, showing publications LEO LUZNIK has written about Histocompatibility.
Connection Strength
1.024
-
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun; 14(6):641-50.
Score: 0.302
-
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 09 10; 3(17):2581-2585.
Score: 0.165
-
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
Score: 0.121
-
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013 Mar; 54(3):655-7.
Score: 0.101
-
Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8.
Score: 0.048
-
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8(7):377-86.
Score: 0.048
-
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 01; 98(12):3456-64.
Score: 0.048
-
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020; 11:636.
Score: 0.043
-
T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biol Blood Marrow Transplant. 2019 05; 25(5):868-882.
Score: 0.039
-
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
Score: 0.034
-
Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol. 2014 Sep; 93(3):187-97.
Score: 0.028
-
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
Score: 0.025
-
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
Score: 0.021